Almirall gets reimbursement deal for Ilumetri in France
Spanish dermatology specialist Almirall (ALM: MC) today announced that it has signed an agreement with the French authorities to make the biologic treatment Ilumetri (tildrakizumab), a high-affinity interleukin (IL)-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy.
The agreement has been signed after the Commission of Transparency of the Haute Autorité de Santé (HAS), the French National Health Authority, provided a favorable opinion for the reimbursement in France of Ilumetri on June 3rd and considered the actual benefit (Service Médical Rendu or SMR) as “important.” The prevalence of chronic plaque psoriasis among the French population is around 5.6%.
First biologic marketed by Almirall
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze